Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RESCUE: A Randomized, Blinded, Placebo-controlled, Parallel Group Design to Determine the Safety of RNS60 in Large Vessel Occlusion Stroke Patients Undergoing Endovascular Thrombectomy

Next Previous
Trial Profile

RESCUE: A Randomized, Blinded, Placebo-controlled, Parallel Group Design to Determine the Safety of RNS60 in Large Vessel Occlusion Stroke Patients Undergoing Endovascular Thrombectomy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Aug 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RNS 60 (Primary)
  • Indications Ischaemic stroke
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms RESCUE
  • Sponsors Revalesio

Most Recent Events

  • 31 Jul 2025 According to a Revalesio media release, the U.S. Food and Drug Administration has granted Fast Track designation to RNS60, its lead investigational therapy, for the treatment of acute ischemic stroke. this granted was based on the Phase 2 RESCUE trial and a supportive preclinical data package.
  • 21 Jul 2025 Primary endpoint (Mortality: proportion of participants alive) has been met, as per results presented in the Revalesio Media Release.
  • 21 Jul 2025 Primary endpoint (Proportion of subjects with serious adverse events) has been met, as per results presented in the Revalesio Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top